Form 4: Avalo Therapeutics CSO Reports Stock Transaction

Chief Strategy Officer Jennifer Riley reported the disposition of 588 shares of Avalo Therapeutics common stock to cover tax obligations.

Summary

• Jennifer Riley, Chief Strategy Officer of Avalo Therapeutics, Inc. (AVTX), executed a transaction on June 10, 2026.
• The transaction involved the disposition of 588 shares of common stock at a price of $13.10 per share.
• The disposition was coded as 'F', indicating shares withheld to satisfy tax withholding obligations related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 39,696 shares of common stock.
• The total includes 3,429 shares acquired through the company's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary sale of stock.

Positives

• The reporting person continues to hold a significant position of 39,696 shares, indicating ongoing alignment with shareholder interests.
• The acquisition of 3,429 shares via the Employee Stock Purchase Plan demonstrates active participation in the company's equity incentive programs.

Negatives

• The transaction represents a reduction in direct share ownership, albeit for tax purposes.

Risks

• General market volatility affecting the valuation of equity holdings.
• Reliance on company-specific equity plans for compensation and wealth accumulation.

Future Outlook

No specific forward-looking guidance regarding company operations or financial performance was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of insider activity related to tax withholding on vested equity, which is standard practice for corporate executives in the biotechnology sector.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for executive compensation and tax compliance.
• The use of 'sell-to-cover' transactions is common among executives at peer biotech firms to manage tax liabilities arising from equity vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related withholding.

Next Steps

• Continued monitoring of future Form 4 filings for changes in executive ownership positions.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Form 4, Insider Trading, Chief Strategy Officer, Equity Compensation